Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BVSNASDAQ:DCTHOTCMKTS:EDTXFNASDAQ:EMBC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBVSBioventus$6.71$7.08$5.28▼$14.38$551.19M0.86454,424 shs239,398 shsDCTHDelcath Systems$15.64-2.0%$13.88$7.12▼$18.23$544.68M0.95387,156 shs460,310 shsEDTXFSpectral Medical$0.65+4.0%$0.58$0.32▼$0.65$184.41M0.2315,863 shs13,677 shsEMBCEmbecta$10.04-0.7%$11.49$9.76▼$21.48$586.77M1.13479,680 shs878,115 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBVSBioventus-2.19%+2.76%-0.45%-30.18%+2.76%DCTHDelcath Systems-1.54%-2.56%+10.45%+32.12%+131.98%EDTXFSpectral Medical+3.93%+3.96%+1.87%+33.19%+69.76%EMBCEmbecta-0.20%-2.79%-18.53%-22.23%-18.60%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBVSBioventus2.563 of 5 stars3.30.00.00.00.04.21.3DCTHDelcath Systems3.6278 of 5 stars3.55.00.00.03.32.50.6EDTXFSpectral Medical0.5448 of 5 stars0.05.00.00.01.80.00.0EMBCEmbecta4.2788 of 5 stars3.21.03.30.01.43.33.8Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBVSBioventus 2.67Moderate Buy$14.33113.61% UpsideDCTHDelcath Systems 3.00Buy$24.0053.45% UpsideEDTXFSpectral Medical 0.00N/AN/AN/AEMBCEmbecta 2.33Hold$19.3392.56% UpsideCurrent Analyst Ratings BreakdownLatest EDTXF, EMBC, DCTH, and BVS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/23/2025EMBCEmbectaBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$25.005/23/2025DCTHDelcath SystemsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $29.005/23/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$15.00 ➝ $13.005/7/2025BVSBioventusCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$15.004/10/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$15.004/9/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold3/17/2025BVSBioventusCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBVSBioventus$567.70M0.97$0.53 per share12.58$2.80 per share2.40DCTHDelcath Systems$53.85M10.11N/AN/A$0.72 per share21.72EDTXFSpectral Medical$1.18M156.28N/AN/A($0.04) per share-16.17EMBCEmbecta$1.08B0.54$2.32 per share4.32($13.23) per share-0.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBVSBioventus-$156.23M-$0.48N/A14.59N/A-7.11%15.61%4.01%N/ADCTHDelcath Systems-$47.68M-$0.50N/AN/AN/A-150.70%-338.16%-104.02%8/4/2025 (Estimated)EDTXFSpectral Medical-$11.60M-$0.07N/A∞N/A-1,245.87%N/A-351.89%8/7/2025 (Estimated)EMBCEmbecta$78.30M$0.9010.043.270.785.25%-19.22%11.92%8/8/2025 (Estimated)Latest EDTXF, EMBC, DCTH, and BVS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025EDTXFSpectral MedicalN/A-$0.03N/A-$0.03N/A$0.40 million5/9/2025Q2 2025EMBCEmbecta$0.66$0.70+$0.04$0.40$261.77 million$259.00 million5/8/2025Q1 2025DCTHDelcath Systems$0.10$0.03-$0.07$0.03$16.83 million$19.80 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBVSBioventusN/AN/AN/AN/AN/ADCTHDelcath SystemsN/AN/AN/AN/AN/AEDTXFSpectral MedicalN/AN/AN/AN/AN/AEMBCEmbecta$0.605.98%N/A66.67%N/ALatest EDTXF, EMBC, DCTH, and BVS DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/5/2025EMBCEmbectaquarterly$0.154.51%5/28/20255/28/20256/13/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBVSBioventus1.851.410.99DCTHDelcath SystemsN/A1.341.03EDTXFSpectral MedicalN/A0.220.21EMBCEmbectaN/A2.241.67Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBVSBioventus62.94%DCTHDelcath Systems61.12%EDTXFSpectral MedicalN/AEMBCEmbecta93.83%Insider OwnershipCompanyInsider OwnershipBVSBioventus32.90%DCTHDelcath Systems17.40%EDTXFSpectral Medical1.50%EMBCEmbecta0.42%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBVSBioventus1,20082.14 million54.46 millionNot OptionableDCTHDelcath Systems6034.83 million26.24 millionOptionableEDTXFSpectral Medical29285.12 million280.48 millionNot OptionableEMBCEmbecta1,90058.44 million57.89 millionOptionableEDTXF, EMBC, DCTH, and BVS HeadlinesRecent News About These CompaniesEmbecta (NASDAQ:EMBC) Hits New 12-Month Low - Here's WhyJune 9 at 3:59 PM | marketbeat.comEmbecta (NASDAQ:EMBC) Reaches New 1-Year Low - Here's What HappenedJune 3, 2025 | marketbeat.comEmbecta Corp. (NASDAQ:EMBC) Short Interest Down 20.1% in MayJune 2, 2025 | marketbeat.comNuveen Asset Management LLC Decreases Position in Embecta Corp. (NASDAQ:EMBC)June 2, 2025 | marketbeat.comEmbecta (NASDAQ:EMBC) Trading Down 4.9% - Here's WhyMay 30, 2025 | marketbeat.comAmeriprise Financial Inc. Reduces Position in Embecta Corp. (NASDAQ:EMBC)May 29, 2025 | marketbeat.comEmbecta (NASDAQ:EMBC) Trading 6.3% Higher - Time to Buy?May 28, 2025 | marketbeat.comembecta to Participate in Investor EventsMay 27, 2025 | globenewswire.comJane Street Group LLC Has $846,000 Stock Position in Embecta Corp. (NASDAQ:EMBC)May 26, 2025 | marketbeat.comEmbecta (NASDAQ:EMBC) Price Target Lowered to $13.00 at MizuhoMay 25, 2025 | marketbeat.comIndependent Non-Executive Chairman of Embecta Picks Up 13% More StockMay 25, 2025 | finance.yahoo.comDavid F. Melcher Purchases 10,000 Shares of Embecta Corp. (NASDAQ:EMBC) StockMay 24, 2025 | insidertrades.comOMERS ADMINISTRATION Corp Trims Stock Position in Embecta Corp. (NASDAQ:EMBC)May 23, 2025 | marketbeat.comEmbecta eyes shift from insulin delivery to broader medical supplies focusMay 22, 2025 | drugdeliverybusiness.comembecta to Showcase Phased Approach for Value Creation and Present Long Range Financial Plan at 2025 Analyst and Investor DayMay 22, 2025 | globenewswire.comJacobs Levy Equity Management Inc. Lowers Position in Embecta Corp. (NASDAQ:EMBC)May 18, 2025 | marketbeat.comEmbecta Corp. (NASDAQ:EMBC) Stock Holdings Increased by Northern Trust CorpMay 18, 2025 | marketbeat.comEmbecta: Not Nearly As Cheap As The 4x Forward P/E Ratio Would ImplyMay 15, 2025 | seekingalpha.comMeros Investment Management LP Purchases 57,312 Shares of Embecta Corp. (NASDAQ:EMBC)May 15, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Trims Position in Embecta Corp. (NASDAQ:EMBC)May 15, 2025 | marketbeat.comEmbecta (NASDAQ:EMBC) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPSMay 12, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEDTXF, EMBC, DCTH, and BVS Company DescriptionsBioventus NYSE:BVS$6.71 0.00 (0.00%) As of 04:00 PM EasternBioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.Delcath Systems NASDAQ:DCTH$15.64 -0.32 (-2.01%) As of 04:00 PM EasternDelcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.Spectral Medical OTCMKTS:EDTXF$0.65 +0.02 (+3.99%) As of 10:01 AM EasternSpectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.Embecta NASDAQ:EMBC$10.04 -0.07 (-0.69%) As of 04:00 PM EasternEmbecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ignore the Noise—Samsara Stock Is Still a Strong Buy Oracle’s Cloud Boom Is Just Getting Started Netflix Sets New Highs—Price Targets Keep Climbing IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA Alibaba’s Dip Is a Gift—Here’s the Price That Matters Betting on Disruption: Is Lemonade the Future of Insurance? Starbucks Stock: Culture Fix May Be Key to Long-Term Growth GameStop Turns a Profit, But Core Business Keeps Shrinking Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
